



**We Claim:**


1. 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1




2. A pharmaceutical composition comprising:
- (a) the compound according to claim 1; and
  - (b) a pharmaceutically acceptable excipient.
3. A method of treating diseases in which inhibition of the cellular  $\text{Na}^+/\text{H}^+$  exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 1.
4. The method according to claim 3, wherein the compound according to claim 1 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.
5. A method of treating diseases in which inhibition of the cellular  $\text{Na}^+/\text{H}^+$  exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of a hydrate of 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1



6. A method of treating diseases in which inhibition of the cellular Na<sup>+</sup>/H<sup>+</sup> exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of a monohydrate of 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1



7. A method of treating diseases in which inhibition of the cellular Na<sup>+</sup>/H<sup>+</sup> exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of a hemihydrate of 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1



8. The method according to claim 5, wherein the a hydrate of 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1 is administered in the

form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.

9. The method according to claim 6, wherein the monohydrate of 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.

10. The method according to claim 7, wherein the 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.